论文部分内容阅读
目的 :研究舍尼通治疗良性前列腺增生症 (BPH)的疗效。方法 :对门诊 67例患者分组 ,舍尼通组 3 7例单用舍尼通治疗 ,联合用药组 3 0例应用舍尼通和特拉唑嗪治疗。结果 :舍尼通组治疗 10个月后症状评分和前列腺体积均有明显改善 (P <0 .0 5 ) ,而尿流率、残余尿量和生存质量评估无明显好转。联合用药组治疗 2个月后最大尿流率和残余尿量有明显改善 (P <0 .0 5 ) ;治疗 10个月后尿流率有进一步改善 ,但前列腺体积和生存质量评估无明显变化。结论 :舍尼通治疗BPH作用缓和 ,适用于轻、中度患者 ,但并不推荐和特拉唑嗪联合应用
Objective: To study the efficacy of chenitone in the treatment of benign prostatic hyperplasia (BPH). Methods: Thirty-seven outpatients were divided into groups, and thirty-seven patients in the senecton group were treated with seneiton alone. Thirty patients in the combination group were treated with senepine and terazosin. Results: The symptom scores and prostate volume were significantly improved after 10 months of treatment in the Senecan group (P <0.05), while no significant improvement was observed in the assessment of urinary flow rate, residual urine volume and quality of life. After 2 months of treatment, the maximum urinary flow rate and residual urine volume were significantly improved (P <0.05). After 10 months of treatment, the urinary flow rate was further improved, but there was no significant change in the assessment of prostate volume and quality of life . Conclusion: Seneiton treatment of BPH alleviate the role of mild to moderate patients, but not recommended and terazosin combination